Tuesday, October 30, 2012
Cytokinetics Inc., of South San Francisco, said it opened its Phase IIb BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) testing tirasemtiv, formerly CK-2017357, in patients with amyotrophic lateral sclerosis (ALS).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.